Teva must pay $235m to GSK for patent infringement
GSK has won a patent case against Teva in which the company will receive $235 million in damages.
The decision was a jury verdict handed down on Tuesday, June 20, at the US District Court for the District of Delaware.
GSK sued Teva in 2014 for filing an Abbreviated New Drug Application seeking to market carvedilol, a class of chemical compounds used to treat patients with high blood pressure and heart failure.
GSK markets carvedilol under the name Coreg, which is covered by US patent number RE40,000, titled “Method of treatment for decreasing mortality resulting from congestive heart failure”.
The company said in its complaint: “Teva knew and intended that its generic copy carvedilol products would be substituted for Coreg even for patients prescribed the drug for treatment of congestive heart failure resulting in the direct infringement of the ‘000 patent.”
The jury also found that Teva had failed to prove that the patent was obvious.
Today’s stories:
Section 101 raises fundamental question: 3M
Panellists tackle patent concerns after Brexit
FBI agent and lawyers provide trade secret tips
Industry at a crossroads over section 101
Pfizer and Takeda help to tackle Africa cancer crisis
Academic patents gave $1.3tn to US output
David Cameron talks Brexit, Trump and genomes
Hospira sued for infringing allergic injection patent
Google’s parent company invests $300m in biotech
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
